Guilin Sanjin   Report issue

For profit Phase 1 Phase 2
Founded: Guilin China (1967)
Status: No NME R&D (1967)

Organization Overview

First Clinical Trial
2018
NCT03491709
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Dragonboat Biopharmaceutical Company Limited

Active Ingredients

Drugs in Phase 2 Trials (1)

ldp (3 trials)

Drugs in Phase 1 Trials (3)

bc006 (1 trial)

CDP1 (3 trials)

cetuximab (erbitux) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 1)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 4